Nurix Therapeutics (NASDAQ:NRIX) Given Overweight Rating at Stephens
Stephens restated their overweight rating on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $31.00 price objective on the stock. NRIX has been the subject of several other reports. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a […]
More Stories
OFG Bancorp (NYSE:OFG) Issues Quarterly Earnings Results
OFG Bancorp (NYSE:OFG – Get Free Report) posted its quarterly earnings data on Wednesday. The bank reported $1.00 earnings per...
Abbott Laboratories (NYSE:ABT) Announces Earnings Results, Beats Estimates By $0.01 EPS
Abbott Laboratories (NYSE:ABT – Get Free Report) released its quarterly earnings results on Wednesday. The healthcare product maker reported $1.21...
Home Bancshares, Inc. (Conway, AR) (NYSE:HOMB) Issues Quarterly Earnings Results
Home Bancshares, Inc. (Conway, AR) (NYSE:HOMB – Get Free Report) announced its earnings results on Wednesday. The financial services provider...
U.S. Bancorp (NYSE:USB) Announces Earnings Results
U.S. Bancorp (NYSE:USB – Get Free Report) issued its earnings results on Wednesday. The financial services provider reported $1.03 EPS...
Abbott Laboratories (NYSE:ABT) Updates FY 2024 Earnings Guidance
Abbott Laboratories (NYSE:ABT – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance...
Just Eat Takeaway.com (OTC:JTKWY) Lifted to Hold at Sanford C. Bernstein
Just Eat Takeaway.com (OTC:JTKWY – Get Free Report) was upgraded by investment analysts at Sanford C. Bernstein to a “hold”...